Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10546066 | 0.84 | GFER (0.47) | ALDH1A1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL10545823 | 0.82 | HTT (0.57) | ALDH1A1NPC1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL13396265 | 0.81 | HPGD (0.56) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| SCHEMBL948160 | 0.81 | HPGD (0.56) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| SCHEMBL7056333 | 0.81 | HPGD (0.56) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| SCHEMBL2185023 | 0.81 | MLYCD (0.65) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| SCHEMBL26763424 | 0.81 | MLYCD (0.65) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| SCHEMBL7462269 | 0.80 | ALDH1A1 (0.55) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL9638714 | 0.79 | MLYCD (0.62) | ALDH1A1NPC1HPGDKMT2ALMNA | |
| SCHEMBL12706226 | 0.78 | ALDH1A1 (0.65) | ALDH1A1NPC1HPGDKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2349351-A2 | IMAGING AND RADIOTHERAPY METHODS | GE Healthcare Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | ALDH1A1 3/4885NPC1 1239/4885HPGD 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.